How to Fight Insurance Denials for Eosinophilic Esophagitis (EoE) Treatment

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus that has increased five-fold over the past two decades. It causes dysphagia, food impaction, and can lead to esophageal strictures if untreated. The FDA approved the first two dedicated EoE drugs only recently—Dupixent (dupilumab) in May 2022 and Eohilia (budesonide oral suspension) in February 2024. Before that, gastroenterologists relied on off-label swallowed corticosteroids (fluticasone or compounded budesonide), high-dose proton pump inhibitors (PPIs), and food-elimination diets. Despite these new approvals and decades of published evidence, insurers routinely deny coverage for EoE therapies, citing step-therapy requirements, experimental or investigational policies, or arbitrary histology thresholds. This guide walks you through the most common denial templates and how to counter them with the specific medical evidence and policy language that payers respect.

Why Insurers Deny EoE Treatment

1. Step-therapy requirements: "Fail two swallowed steroids (and sometimes an elimination diet) before Dupixent"

Many prior-authorization policies require patients to document failure, intolerance, or contraindication to two swallowed corticosteroids—usually fluticasone and compounded budesonide—and sometimes also demand a trial of empiric elimination diet before approving Dupixent. Insurers frame this as "cost-effective sequential therapy," even though the 2020 clinical guidelines list these modalities as parallel first-line options, not a mandatory ladder.

2. "Eohilia is not medically necessary—compounded budesonide or fluticasone are cheaper alternatives"

Eohilia, the first FDA-approved swallowed steroid, carries a list price significantly higher than off-label fluticasone metered-dose inhaler puff-and-swallow or pharmacy-compounded budesonide. Insurers argue that these off-label regimens are "therapeutically equivalent" and deny Eohilia as duplicative or non-preferred.

3. "Histologic remission not documented" or "Diagnosis does not meet threshold"

Some medical directors will cite an outdated peak eosinophil count threshold or argue that the patient's biopsy report does not clearly demonstrate ≥15 eosinophils per high-power field (eos/HPF). Others demand repeat endoscopy on proton pump inhibitor therapy to exclude PPI-responsive esophageal eosinophilia (PPI-REE) before approving any additional therapy, even when a PPI trial has already been documented.

4. "Dupixent for EoE is experimental/investigational" or "Age/weight criteria not met"

Despite FDA approval in May 2022 for patients 12 years and older and expansion in January 2024 to ages 1 year and up (≥15 kg), a handful of plans have not updated their medical policies. You may see blanket "investigational" denials or requirements that the patient be 12 or older, ignoring the pediatric label expansion.

5. "Endoscopic dilation should be tried first" or "Dietary elimination not attempted"

Payers sometimes treat fibrostenotic complications (strictures, rings) and the underlying type-2 inflammation as if one "cure" substitutes for the other. Dilation physically stretches scar tissue but does nothing to reduce eosinophilic inflammation; dietary elimination can achieve histologic remission in some patients but is difficult to sustain and does not work for everyone. Nevertheless, insurers may deny pharmacotherapy until these have been "exhausted."

The Citations Insurers Respect

When you appeal, reference the following guidelines and trials by name and year. Medical directors know these documents, and citing them precisely signals that your appeal is clinically grounded.

• ACG Clinical Guideline: Evidence-Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE), American Journal of Gastroenterology 2020 – The American College of Gastroenterology consensus document that lists PPIs, swallowed topical corticosteroids, dietary elimination, and biologics as parallel first-line options with no mandated treatment sequence.

• AGA/AAAAI/ACAAI/APFED Joint Task Force on Eosinophilic Gastrointestinal Diseases (JTF) Multidisciplinary Guidelines, Gastroenterology and Journal of Allergy and Clinical Immunology 2020 – Multi-society evidence review concluding that PPI, swallowed steroids, elimination diets, and biologics are all acceptable initial therapies depending on patient preference, phenotype, and comorbidities.

• LIBERTY EoE TREET (Parts A and B), New England Journal of Medicine 2022 – The two pivotal Phase 3 randomized controlled trials of Dupixent (dupilumab) 300 mg subcutaneous weekly in adolescents and adults with EoE. Part A (24 weeks) showed 60 % histologic remission (≤6 eos/HPF) versus 5 % placebo; Part B (28 additional weeks) demonstrated sustained remission and symptom improvement in responders.

• Eohilia (budesonide oral suspension) FDA Approval, February 2024 (adults) and May 2024 (ages 11+) – The two Phase 3 trials in adults (BOS-2) and adolescents (BOS-3) showed histologic remission rates of approximately 88 % and 86 % at 12 weeks versus placebo (4–6 %), with standardized dosing (2 mg twice daily) and vehicle designed to coat the esophagus.

• AGREE (American Gastroenterological Association Institute and Joint Task Force) International Consensus Diagnostic Criteria for EoE, Gastroenterology 2018 – Established the diagnostic threshold of ≥15 peak eosinophils per high-power field in at least one esophageal biopsy specimen, with ≥6 biopsies from at least two esophageal levels recommended.

• Kliewer et al., Lancet Gastroenterology & Hepatology 2023: One-Food Elimination Diet (1FED, cow's milk only) – Multicenter European study showing that eliminating cow's milk alone achieved histologic remission in about 34 % of adults, establishing 1FED as a simpler alternative to six-food or four-food elimination diets.

• Dellon et al., Gastroenterology 2018: EoE Epidemiology and Natural History – Population-based data documenting the five-fold increase in EoE incidence over two decades and the progressive fibrostenotic remodeling that occurs without anti-inflammatory treatment.

• Dupixent Prescribing Information, January 2024 Update – The FDA-approved label now includes EoE indication for patients 1 year of age and older weighing at least 15 kg, based on the pediatric EoE KIDS trial.

How to Argue Against Each Denial Reason

1. Countering step-therapy: "Must fail two swallowed steroids before Dupixent"

Your position: ACG 2020 and AGA/JTF 2020 explicitly state that PPIs, swallowed topical corticosteroids, dietary elimination, and biologics are parallel first-line treatment options with no mandated sequence. The guidelines recommend shared decision-making based on patient phenotype, comorbidities, and preference—not a cost-driven step protocol.

Concrete steps:

• Quote the guidelines verbatim. ACG 2020 states: "We suggest the use of PPIs, topical steroids, elimination diet, or biologics as initial treatment options in adults with EoE (conditional recommendation, low quality of evidence)." Note the word or, not then.
• Highlight patient-specific factors. If your patient has already tried a PPI (e.g., omeprazole 40 mg twice daily for 8–12 weeks) and one swallowed steroid (e.g., fluticasone 880 mcg twice daily for 12–16 weeks) with inadequate response (repeat biopsy still ≥15 eos/HPF), document those trials in detail: drug, dose, duration, adherence, and post-treatment endoscopy findings.
• Note atopic comorbidities. If the patient has moderate-to-severe atopic dermatitis, asthma, or allergic rhinitis, cite that Dupixent targets the shared IL-4/IL-13 pathway and is already FDA-approved for these conditions. This makes Dupixent the logical choice to treat multiple type-2 inflammatory diseases simultaneously.
• Cite LIBERTY EoE TREET enrollment criteria. The pivotal trials enrolled both patients naïve to swallowed steroids and those who had previously used them; FDA approval was not conditioned on prior steroid failure.
• Request an external review or expedited appeal if the patient has a history of food impaction or severe dysphagia; delayed treatment can lead to emergency-department visits and urgent endoscopic disimpaction.

2. Countering "Use compounded budesonide or fluticasone instead of Eohilia"

Your position: Compounded budesonide slurries and off-label fluticasone MDI have no FDA-approved formulation, no standardized dosing, and variable bioavailability. Eohilia is the only FDA-approved swallowed steroid with a vehicle specifically engineered to adhere to esophageal mucosa and deliver consistent drug concentration.

Concrete steps:

• Emphasize lack of FDA approval for alternatives. Off-label regimens rely on clinic-by-clinic or pharmacy-by-pharmacy recipes (e.g., budesonide respules mixed with sucralose, or fluticasone MDI puff-and-swallow). There is no quality-control standard, and compounding pharmacies may not be available or covered by the patient's plan.
• Document prior failure or intolerance of off-label options. If the patient tried fluticasone or compounded budesonide and had inadequate response (repeat EGD showing persistent ≥15 eos/HPF) or developed oral candidiasis, include those records.
• Quote the Eohilia prescribing information. The FDA-approved dose is 2 mg twice daily, and the pivotal trials (BOS-2 in adults, BOS-3 in adolescents) showed histologic remission rates near 90 % at 12 weeks.
• Note that some state Medicaid and commercial plans have already added Eohilia to formulary following the February 2024 approval; request parity with those coverage decisions.
• Appeal on the basis of safety and adherence. A standardized, FDA-approved product reduces risk of dosing errors and improves adherence, particularly in pediatric and adolescent populations.

3. Countering "Histologic remission not documented" or "Does not meet diagnostic threshold"

Your position: The AGREE 2018 consensus diagnostic criteria define EoE as ≥15 peak eosinophils per high-power field in any single HPF across multiple biopsies, with symptoms of esophageal dysfunction. Peak count matters—you do not average across all specimens.

Concrete steps:

• Attach the full pathology report showing the highest eos/HPF in any biopsy fragment. Highlight the peak count (e.g., "proximal esophagus 28 eos/HPF, distal esophagus 42 eos/HPF → peak 42 eos/HPF").
• Confirm adequate biopsy sampling. AGREE and ACG 2020 recommend ≥6 biopsies from at least two levels (proximal and distal esophagus). If your endoscopist took fewer, note that in some cases even two well-targeted biopsies can establish the diagnosis, but best practice is six.
• Clarify PPI-responsive EoE (PPI-REE). If the insurer demands exclusion of PPI-REE, document that the patient was on a PPI (e.g., omeprazole 40 mg twice daily) for 8–12 weeks before the diagnostic EGD, and eosinophilia persisted. AGREE recognizes PPI-REE as part of the EoE spectrum, and treatment approach is identical.
• Include endoscopic findings. Reference the EREFS score (Edema, Rings, Exudates, Furrows, Stricture) from the endoscopy report. Features like rings, furrows, and strictures support the EoE diagnosis even if the insurer questions the eos count.
• Cite natural-history data (Dellon Gastroenterology 2018) showing that untreated EoE leads to progressive fibrostenotic remodeling. Delayed treatment increases the risk of food impaction and need for repeated dilations.

4. Countering "Dupixent for EoE is experimental/investigational" or age/weight denials

Your position: Dupixent received FDA approval for EoE in May 2022 for patients 12 years and older, and the indication was expanded in January 2024 to include patients as young as 1 year of age weighing ≥15 kg, based on the pediatric EoE KIDS trial.

Concrete steps:

• Attach the current FDA-approved prescribing information (January 2024 version) showing the pediatric EoE indication for ages 1+ and weight ≥15 kg.
• Reference LIBERTY EoE TREET Parts A and B (NEJM 2022) and the pediatric EoE KIDS trial data that supported label expansion.
• Request that the medical policy be updated. If the denial letter cites an outdated policy (e.g., "investigational for EoE" or "approved only ≥12 years"), write: "The plan's medical policy appears not to reflect the current FDA-approved indication. I request an immediate update to align with the January 2024 prescribing information and approval of this prior authorization under the updated indication."
• Cite your state's prompt-payment and timely-review laws. Many states require insurers to make prior-auth decisions within 72 hours (urgent) or 15 days (non-urgent) and to base denials on current, evidence-based criteria.

5. Countering "Try dilation or diet first"

Your position: Endoscopic dilation treats the mechanical complication (stricture) but does not reduce eosinophilic inflammation. Dietary elimination can induce remission in some patients but requires intensive nutritionist support, takes months to identify triggers, and has high rates of non-adherence. ACG 2020 and AGA/JTF 2020 list all modalities as parallel options.

Concrete steps:

• Document prior dilation history if applicable. If the patient has already undergone one or more dilations (e.g., Savary 16 mm → 18 mm), note that dilation does not prevent recurrent stricture formation and that ongoing anti-inflammatory therapy is required.
• If diet was attempted, detail the results. For example: "Patient completed eight-week six-food elimination diet with registered dietitian. Repeat EGD showed eos 28/HPF (partial response). Milk reintroduction triggered symptom recurrence. Patient and family unable to sustain long-term multiple-food restriction due to nutritional concerns and quality-of-life impact."
• If diet was not attempted, explain why. Common reasons include young age with feeding aversion, high atopic burden with multiple IgE-mediated food allergies (making empiric elimination unsafe), or patient/family preference for pharmacotherapy after informed shared decision-making.
• Cite ACG 2020 language: "The choice of initial therapy should be individualized based on patient preference, age, ability to adhere to dietary restrictions, comorbid atopic conditions, and fibrostenotic versus inflammatory phenotype."
• Highlight the Kliewer Lancet GH 2023 one-food elimination data if the insurer insists on diet: even eliminating only cow's milk achieves remission in only about one-third of adults, meaning two-thirds will require pharmacotherapy regardless.

What We Do

We turn your clinical records—endoscopy reports, pathology, prior-therapy documentation, and comorbidity history—into a fully cited, medically detailed appeal letter that meets or exceeds the payer's own evidence standards. We pull the exact guideline language, trial endpoints, and FDA label updates that medical directors rely on, and we format the letter for both internal appeals and independent external review. Most importantly, we do this fast, so you meet your appeal deadline and get back to the business of treating your EoE rather than fighting bureaucracy.

---

Sources

1. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020;158(6):1776–1786.

2. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–1033.

3. Hirano I, Collins MH, Katzka DA, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis (LIBERTY EoE TREET). N Engl J Med. 2022;387(23):2317–2330.

4. Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319–332.

5. Kliewer KL, Cassin AM, Venter C, et al. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Lancet Gastroenterol Hepatol. 2023;8(5):408–421.

6. US Food and Drug Administration. Dupixent (dupilumab) Prescribing Information. Updated January 2024.

7. US Food and Drug Administration. Eohilia (budesonide oral suspension) Prescribing Information. Approved February 2024.

8. Rothenberg ME, Aceves SS, Bonis PA, et al. Working with the FDA and Partners to Facilitate Drug Development in Eosinophilic Esophagitis: Proceedings from the 2019 CEGIR/FDA-NIH-NIDDK Workshop. J Allergy Clin Immunol Pract. 2020;8(9):2933–2947.